Nova Eye Medical Limited (ASX:EYE)

Market Cap	34.89M +6.8%
Revenue (ttm)	33.05M +26.6%
Net Income	-7.03M
EPS	-0.03
Shares Out	284.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,481
Average Volume	236,719
Open	0.1300
Previous Close	0.1250
Day's Range	0.1200 - 0.1300
52-Week Range	0.1000 - 0.2050
Beta	0.94
RSI	43.36
Earnings Date	Aug 26, 2026

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, t...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1970
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EYE

Financial Performance

In fiscal year 2025, Nova Eye Medical's revenue was 29.27 million, an increase of 25.47% compared to the previous year's 23.33 million. Losses were -9.06 million, 3.06% more than in 2024.